BioStem Technologies, Inc.

OTCPK:BSEM Stock Report

Market Cap: US$67.5m

BioStem Technologies Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Jason Matuszewski

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage15.31%
CEO tenure11.8yrs
CEO ownershipn/a
Management average tenure1.5yrs
Board average tenureless than a year

Recent management updates

Recent updates

User avatar
New Narrative • Mar 10

VENDAJE AC National Launch And BioRetain Data To Drive Future Market Expansion

Strategic collaborations and successful CMS partnerships can enhance market adoption and pricing stability, boosting net margins and profitability.

CEO Compensation Analysis

How has Jason Matuszewski's remuneration changed compared to BioStem Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$19m

Dec 31 2025US$5mUS$750k

-US$7m

Sep 30 2025n/an/a

US$19m

Jun 30 2025n/an/a

US$25m

Mar 31 2025n/an/a

US$32m

Dec 31 2024US$5mUS$369k

US$31m

Sep 30 2024n/an/a

US$16m

Jun 30 2024n/an/a

US$7m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$371kUS$275k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$8mUS$200k

-US$7m

Compensation vs Market: Jason's total compensation ($USD4.90M) is above average for companies of similar size in the US market ($USD658.93K).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.

CEO

Jason Matuszewski (39 yo)

11.8yrs
Tenure
US$4,900,000
Compensation

Mr. Jason V. Matuszewski is Chief Executive Officer of BioStem Technologies, Inc. since October 22, 2019 and serves as its Chairman since May 2025 and served as its Chairman of BioStem Technologies, Inc. s...

Leadership Team

NamePositionTenureCompensationOwnership
Jason Matuszewski
CEO, President11.8yrsUS$4.90mno data
Brandon Poe
Chief Financial Officerless than a yearUS$748.06kno data
Andrew Van Vurst
COO & Directorno dataUS$2.93mno data
Michael Fortunato
Chief Accounting Officerless than a yearUS$1.08mno data
Noah Agron
Vice President of Corporate Finance & Strategy1.2yrsno datano data
Katherine Gorrell
Chief Legal & Compliance Officerless than a yearno datano data
Jeff Humke
Vice President of Human Resources1.5yrsno datano data
David Woynarowski
Chief Medical Officer10.4yrsno datano data
Larry Jones
Chief Revenue Officer8.4yrsno datano data
Irmgard Huber
International Medical Advisor & Interim Chief Medical Officer8.3yrsno datano data
Barry Hassett
Chief Commercial Officer1.5yrsno datano data
1.5yrs
Average Tenure
52.5yo
Average Age

Experienced Management: BSEM's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jason Matuszewski
CEO, President1.2yrsUS$4.90mno data
Andrew Van Vurst
COO & Director10.3yrsUS$2.93mno data
Steven Sonenreich
Independent Directorless than a yearno datano data
Mark Glickman
Independent Directorless than a yearno datano data
Rayna Hannaway
Independent Directorless than a yearno datano data
Kenneth Warrington
Independent Director4.3yrsUS$210.00kno data
Jodi Ungrodt
Independent Directorless than a yearno datano data
0.3yrs
Average Tenure
54yo
Average Age

Experienced Board: BSEM's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/16 23:38
End of Day Share Price 2026/07/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioStem Technologies, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.